News
Humana Expands Value-Based Agreement with Hutchinson Clinic to Increase Medicare Advantage Access in Central Kansas
Humana Inc. (NYSE: HUM), a leading health and wellness company, has expanded its value-based care agreement with Hutchinson Clinic, a physician specialty group with a 60-year legacy of focusing on
Humana Announces Value-Based Agreement with Allina Health in Minnesota
Humana Inc. (NYSE: HUM), a leading health and well-being company, and Allina Health are expanding their existing agreement to focus on value-based care for Humana’s Medicare Advantage members in
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the phase 3 pivotal LUNAR trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with immune
Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the
Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX) today announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in individuals 12 through 15
Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX) today announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in individuals 12 through 15
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas
Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that investigators presented results from the neratinib arm of the Phase II Individualized Screening Trial of
Quidel Presents at 33rd Annual Piper Sandler Healthcare Conference
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it participated in a
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of 9 abstracts that will be presented at the 2021 San Antonio Breast Cancer Symposium (SABCS), to be held
Simulations Plus Names Sharlene Evans to Board of Directors
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the
Dr. Otis Brawley Named to Agilent Board of Directors
Agilent Technologies, Inc. (NYSE: A) today announced that Dr. Otis W. Brawley, a Bloomberg Distinguished Professor with the Department of Oncology and Epidemiology at the Johns Hopkins University
Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis
Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved XELJANZ® (tofacitinib) 5 mg twice daily for the treatment of adults with active ankylosing spondylitis (AS) who
Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis
Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved XELJANZ® (tofacitinib) 5 mg twice daily for the treatment of adults with active ankylosing spondylitis (AS) who
Simulations Plus Presented Breakthrough Scientific Data at Top Liver Disease Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it presented simulation
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID™
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID™
Agilent Increases Cash Dividend to 21 Cents Per Share
Agilent Technologies, Inc. (NYSE: A) today announced the company has increased its quarterly dividend to 21 cents per share of common stock, reflecting an 8% increase over the previous quarter. The
Bronson Healthcare and Acadia Healthcare Break Ground on New Behavioral Health Hospital to Serve Southwest Michigan
Bronson Healthcare and Acadia Healthcare Company today held a virtual groundbreaking ceremony marking the beginning of construction on the new hospital that the two companies are building together
Humana’s Preferred Medicare Part D Network to Include More Than 11,000 Retail Pharmacy Locations in 2022
Humana Inc. (NYSE: HUM), a leading health and well-being company, has announced that many of its Prescription Drug Plan (PDP) members will soon have even more low-cost and convenient options with
Pfizer Completes Acquisition of Trillium Therapeutics
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Trillium Therapeutics, a clinical stage immuno-oncology company developing innovative therapies for the
Pfizer Completes Acquisition of Trillium Therapeutics
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Trillium Therapeutics, a clinical stage immuno-oncology company developing innovative therapies for the